Table 1.

Recapture of treatment response before or after switching to OL IXE through 104 weeks among patients randomised to placebo (IXE withdrawal) who experienced a flare and were retreated

Total patients who flared and were switched to OL IXE retreatment	Placebo (IXE withdrawal) (N=28)
ASDAS disease activity status	LDA	ID
Recaptured response before OL IXE retreatment, n	4	1
Recaptured response with OL IXE retreatment (≤16 weeks), n	23	14
Recaptured response with OL IXE retreatment (>16 weeks), n	0	5
Total patients who recaptured response by week 104, n (%)	27/28 (96)	20/28 (71)

In each column, the denominator is 28. A total of 4 patients met the criteria for flare and were not retreated. 20 patients had achieved ASDAS ID, while 8 patients achieved ASDAS LDA before flare and OL IXE retreatment.

ASDAS, Ankylosing Spondylitis Disease Activity Score; ID, inactive disease; IXE, ixekizumab; LDA, low disease activity including ID; N, number of patients in the analysis population; OL, open-label.